McKesson (MCK Quick QuoteMCK - Free Report) reported $96.3 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 6%. EPS of $11.69 for the same period compares to $10.12 a year ago.

The reported revenue represents a surprise of -5.52% over the Zacks Consensus Estimate of $101.92 billion. With the consensus EPS estimate being $11.56, the EPS surprise was +1.14%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- North American Pharmaceutical: $79.12 billion versus the three-analyst average estimate of $84.12 billion. The reported number represents a year-over-year change of -4.9%.
• Revenue- Medical-Surgical Solutions: $2.87 billion versus the three-analyst average estimate of $2.94 billion. The reported number represents a year-over-year change of +0.5%.
• Revenue- Prescription Technology Solutions: $1.5 billion versus the three-analyst average estimate of $1.47 billion. The reported number represents a year-over-year change of +11.7%.
• Revenue- Oncology & Multispecialty: $12.71 billion versus $12.69 billion estimated by three analysts on average.
• Revenue- Other: $101 million versus $69.63 million estimated by two analysts on average.
• Adjusted Operating Profit- Oncology & Multispecialty: $385 million compared to the $392.25 million average estimate based on three analysts.
• Adjusted Operating Profit- Medical-Surgical Solutions: $271 million compared to the $284.53 million average estimate based on three analysts.
• Adjusted Operating Profit- North American Pharmaceutical: $980 million versus $991.34 million estimated by three analysts on average.
• Adjusted Operating Profit- Prescription Technology Solutions: $322 million compared to the $310.2 million average estimate based on three analysts.
• Adjusted Operating Profit- Corporate: $-209 million versus the two-analyst average estimate of $-197.04 million.
• Adjusted Operating Profit- Other: $8 million compared to the $4.09 million average estimate based on two analysts.

View all Key Company Metrics for McKesson here>>>

Shares of McKesson have returned -14.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.